Hedgehog Pathway Inhibitors Archives

European Commission Approves Libtayo for Two Advanced Cancers

Basal Cell Carcinoma, Blockbusters, European Commission, European Union, Hedgehog Pathway Inhibitors, New Indications, Non-Small Cell Lung Cancer (NSCLC), Overall Survival (OS), Regeneron Pharmaceuticals, Sanofi, Therapeutics

Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved the PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. The EC also approved Libtayo in advanced basal cell carcinoma (BCC).

Regeneron and Sanofi Collaboration Receives Third FDA Drug Approval

Advanced Non-Small Cell Lung Cancer, Approvals, Blockbusters, Chemoradiation, Clinical Trials, FDA, Hedgehog Pathway Inhibitors, Monoclonal Antibodies, New Indications, PD-1/PD-L1 inhibitors, Progression-Free Survival (PFS), R&D, Regeneron Pharmaceuticals, Sanofi, Therapeutics, Tumors

Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.

Regeneron and Sanofi’s Checkpoint Inhibitor Shines in Phase II BCC Study

Basal Cell Carcinoma, Business, Checkpoint Inhibitors, Clinical Data, Clinical Trials, European Society for Medical Oncology (ESMO), Hedgehog Pathway Inhibitors, Partnerships, PD-1 Inhibitors, R&D

Regeneron and Sanofi broke new ground in treating advanced basal cell carcinoma with their anti-PD-1 inhibitor, Libtayo.